";s:4:"text";s:5282:" Autoimmune hepatitis (AIH) is an organ-specific autoim-mune disease characterized by a break of humoral and cel-lular immunotolerance that mainly affects the liver, although extrahepatic manifestations are also observed in approximately 25% of patients.1 The disease was first described in 1951 in young women …
The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer. Alvarez F, Berg PA, Bianchi FB, et al.
Richardson PD, James PD, Ryder SD.
Kirk AP, Jain S, Pocock S, et al.
[Guideline] Manns MP, Czaja AJ, Gorham JD, et al. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. Genetic predispositions for the immunological features of chronic active hepatitis. Czaja AJ.
Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.
Data sources: Literature was accessed through PubMed/MEDLINE (1966-June 2011) and Web of Science (1965-June 2011) using the terms autoimmune hepatitis and budesonide.
Autoimmune chronic active hepatitis associated with the presence of antiphospholipid antibodies.
2 Budesonide is an alternative to conventional steroids for the induction of remission, but it should not be given to patients with cirrhosis, and data on … Meeting report: International Autoimmune Hepatitis Group.
Use of any information is solely at the user's own risk. However, there has never been a randomized, controlled trial of this treatment approach in autoimmune hepatitis.
• Autoimmune hepatitis. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
The dose of azathioprine was increased to 2 mg per kilogram per day, and the prednisolone was gradually withdrawn.
Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.
2001
Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Literature was limited to English-language publications. (Optional) Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
8 Mycophenolate mofetil is another choice as second‐line therapy and is given at doses of 1.5 to 2.0 g/day. Moscow, 2018). Wang Q, Yang F, Miao Q, Krawitt EL, Gershwin ME, Ma X.
[Guideline] Dalekos GN, Koskinas J, Papatheodoridis GV.
Feldman M, Scharschmidt BF, Sleisenger MH, eds. A number of my patients have been on high-dose prednisone over long periods of time and have developed metabolic syndrome and nonalcoholic fatty liver disease. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Available at Woynarowski M, Nemeth A, Baruch Y, et al, for the European Autoimmune Hepatitis-Budesonide Study Group. Fernandes NF, Redeker AG, Vierling JM, et al.
Czaja AJ. In addition, references from publications identified were reviewed. Treatment of autoimmune hepatitis. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. Reich DJ, Fiel I, Guarrera JV, et al.
2010
Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Than NN, Wiegard C, Weiler-Normann C, et al. 2002
172356-overview
Autoimmune hepatitis (AIH) ... Cyclosporin A should be given at doses of 2 to 5 mg/kg/day to achieve 100 to 300 ng/mg of blood levels, and tacrolimus should be given at doses of 3 to 5 mg/kg twice daily. Tucker SM, Jonas MM, Perez-Atayde AR. Select one or more newsletters to continue.
Patients with low or absent TPMT activity are at an increased risk of developing severe, life threatening myelotoxicity from azathioprine.